The oncology market will show dramatic development in both overall size and content over the next decade. As the value of the market for traditional therapies is driven down, and more innovative therapies are launched, pharmaceutical companies will need to adapt their product development and marketing strategies. Datamonitor’s Drugs of Tomorrow: Cancer Overview analyses the current state and future trends in the cancer market, with reference to both treatment classes, and dominant companies. Ten tumor types are examined, including evaluation of current treatment regimens and unmet needs. Pipeline products in clinical trials are presented, with detailed analyses of all phase III agents, and sales forecasting until 2010. An extensive analysis of key pharmaceutical companies and biotechnology companies is also presented.
